Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors
Authors
Keywords
Erdafitinib, Phase 1, Safety, Pharmacokinetics, Pharmacodynamics
Journal
INVESTIGATIONAL NEW DRUGS
Volume 36, Issue 3, Pages 424-434
Publisher
Springer Nature
Online
2017-09-30
DOI
10.1007/s10637-017-0514-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer withFGFR1amplification: A single-arm, phase 2 study
- (2016) Sung Hee Lim et al. CANCER
- Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
- (2016) Ann-Lii Cheng et al. HEPATOLOGY
- FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
- (2016) MASARU KATOH INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) Jonathan A Ledermann et al. LANCET
- FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers
- (2015) F. Goke et al. CLINICAL CANCER RESEARCH
- Targeting FGFR Signaling in Cancer
- (2015) M. Touat et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
- (2015) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial
- (2015) R Paul Symonds et al. LANCET ONCOLOGY
- FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors
- (2015) F. Li et al. Cancer Discovery
- Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
- (2014) Matthew I. Milowsky et al. EUROPEAN JOURNAL OF CANCER
- A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
- (2014) Matthew A. Powell et al. GYNECOLOGIC ONCOLOGY
- FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder
- (2014) Elizabeth A. Guancial et al. Cancer Medicine
- Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
- (2013) R. Dienstmann et al. ANNALS OF ONCOLOGY
- Effect of inhibition of the FGFR–MAPK signaling pathway on the development of ocular toxicities
- (2013) Ruud van der Noll et al. CANCER TREATMENT REVIEWS
- Mechanisms of FGFR-mediated carcinogenesis
- (2012) Imran Ahmad et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
- (2012) P. R. Gavine et al. CANCER RESEARCH
- Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
- (2012) A. N. Brooks et al. CLINICAL CANCER RESEARCH
- Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
- (2012) D. Singh et al. SCIENCE
- Fibroblast growth factors and their receptors in cancer
- (2011) Jørgen Wesche et al. BIOCHEMICAL JOURNAL
- FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone
- (2011) Simon Wöhrle et al. JOURNAL OF BONE AND MINERAL RESEARCH
- FGFR2 alterations in endometrial carcinoma
- (2011) Sonia Gatius et al. MODERN PATHOLOGY
- Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer
- (2011) J. Baselga ONCOLOGIST
- A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
- (2010) D. J. Jonker et al. ANNALS OF ONCOLOGY
- Roles of Fibroblast Growth Factor Receptors in Carcinogenesis
- (2010) E. M. Haugsten et al. MOLECULAR CANCER RESEARCH
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- (2010) J. Weiss et al. Science Translational Medicine
- Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer
- (2009) D. C. Tomlinson et al. CANCER RESEARCH
- The FGF family: biology, pathophysiology and therapy
- (2009) Andrew Beenken et al. NATURE REVIEWS DRUG DISCOVERY
- The FGF23–Klotho axis: endocrine regulation of phosphate homeostasis
- (2009) M. Shawkat Razzaque Nature Reviews Endocrinology
- Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies
- (2009) Yongping Crawford et al. TRENDS IN PHARMACOLOGICAL SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started